Effects_NNS
of_IN
glucocorticoids_NNS
on_IN
transcription_NN
factor_NN
activation_NN
in_IN
human_JJ
peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
._.

Glucocorticoids_NNS
have_VBP
an_DT
inhibitory_JJ
effect_NN
on_IN
inflammatory_JJ
and_CC
immune_JJ
responses_NNS
,_,
and_CC
this_DT
may_MD
be_VB
through_IN
the_DT
modulation_NN
of_IN
transcription_NN
factor_NN
binding_NN
to_TO
DNA_NN
._.

The_DT
interaction_NN
of_IN
the_DT
transcription_NN
factors_NNS
,_,
activator_NN
protein-1_NN
-LRB-_-LRB-
AP-1_NN
-RRB-_-RRB-
,_,
nuclear_JJ
factor_NN
kappa_NN
B_NN
-LRB-_-LRB-
NF_NN
kappa_NN
B_NN
-RRB-_-RRB-
,_,
and_CC
cAMP-responsive_JJ
element_NN
binding_NN
protein_NN
-LRB-_-LRB-
CREB_NN
-RRB-_-RRB-
with_IN
DNA_NN
and_CC
glucocorticoid_NN
receptors_NNS
-LRB-_-LRB-
GR_NN
-RRB-_-RRB-
was_VBD
analyzed_VBN
in_IN
human_JJ
peripheral_JJ
blood_NN
mononuclear_JJ
cells_NNS
by_IN
gel_NN
mobility_NN
shift_NN
assays_NNS
._.

TNF-alpha_NN
,_,
IL-1_NN
beta_NN
and_CC
phorbol_NN
myristate_NN
acetate_NN
-LRB-_-LRB-
PMA_NN
-RRB-_-RRB-
treatment_NN
increased_VBD
AP-1_NN
and_CC
NF_NN
kappa_NN
B_NN
DNA_NN
binding_NN
by_IN
up_RB
to_TO
200_CD
%_NN
but_CC
decreased_VBD
CREB_NN
binding_NN
-LRB-_-LRB-
38_CD
%_NN
-RRB-_-RRB-
over_IN
a_DT
60-min_JJ
time_NN
course_NN
._.

Dexamethasone_NN
produced_VBD
a_DT
rapid_JJ
and_CC
sustained_JJ
increase_NN
in_IN
glucocorticoid_NN
response_NN
element_NN
binding_NN
and_CC
a_DT
concomitant_JJ
40-50_CD
%_NN
decrease_NN
in_IN
AP-1_NN
,_,
NF_NN
kappa_NN
B_NN
,_,
and_CC
CREB_NN
DNA_NN
binding_NN
that_WDT
was_VBD
blocked_VBN
by_IN
combined_JJ
dexamethasone_NN
and_CC
cytokine_NN
or_CC
PMA_NN
treatment_NN
._.

These_DT
latter_JJ
effects_NNS
were_VBD
due_JJ
to_TO
increases_NNS
in_IN
the_DT
nuclear_JJ
localization_NN
of_IN
GR_NN
,_,
not_RB
to_TO
reduced_VBN
amounts_NNS
of_IN
the_DT
other_JJ
transcription_NN
factors_NNS
._.

This_DT
suggests_VBZ
that_IN
in_IN
these_DT
cells_NNS
GR_NN
within_IN
the_DT
nucleus_NN
interacts_VBZ
with_IN
cytokine-stimulated_JJ
transcription_NN
factors_NNS
by_IN
the_DT
process_NN
of_IN
cross_JJ
coupling_NN
._.

This_DT
may_MD
be_VB
an_DT
important_JJ
molecular_JJ
site_NN
of_IN
steroid_NN
action_NN
._.

